Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript

 Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of
                    Rosetta Cancer Origin Test Manuscript

Fifth Validation Study Demonstrating Ability to Identify Tumor Origin in
Patients with Cancer of Unknown or Uncertain Primary Shows 92% Accuracy,
Highest Published Level to Date

PR Newswire

PHILADELPHIA and REHOVOT, Israel, June 6, 2013

PHILADELPHIA and REHOVOT, Israel, June 6, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces that a manuscript reporting
data validating the clinical utility of the Rosetta Cancer Origin Test^™
(formerly miRview^® mets^2) to identify the tumor of origin in Cancer of
Unknown or Uncertain Primary (CUP) has been accepted for publication in the
peer-reviewed on-line journal Molecular Cancer. The article, titled "Novel
microRNA-based assay demonstrates 92% agreement with diagnosis based on
clinicopathologic and management data in a cohort of patients with carcinoma
of unknown primary," represents the seventh peer-reviewed publication relating
to our CUP assays, and the fifth peer-reviewed publication relating to post
market validation studies demonstrating the Cancer Origin Test's ability to
identify tumor origin in CUP with 92% concordance, the highest level of
accuracy of any similar study published to date.

The manuscript discusses the performance of the Cancer Origin Test, an assay
utilizing 64 microRNAs to identify 42 tumor types, in formalin-fixed
paraffin-embedded (FFPE) samples from 84 CUP patients The results showed
concordance with the final diagnosis in 92% of patients; representing an
improvement in agreement of 22 percentage points from presentation diagnosis
to final diagnosis, which final diagnosis wasachieved after more precise
clinical and pathological data was added to the data relied upon for the
patient's initial assessment.

"MicroRNAs are particularly well-suited as biomarkers for identifying tumor
origin as their expression levels and profile reflects tissue origin.
Importantly, microRNAs have been shown to be highly stable in tissue blocks,
the most common and readily available specimen type in pathology. Profiling
microRNA from FFPE tissue has been described to be superior to mRNA profiling,
since the latter are prone to extensive degradation in FFPE samples," stated
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
"These data are important as they continue to confirm the clinical utility and
extremely high level of concordance with the final diagnosis in real-world CUP
patients. The availability and accuracy of our Cancer Origin Test underscores
why the uncertainty of CUP is no longer acceptable."

According to E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics' Chief
Medical Officer, "CUP presents clinicians with a diagnostic as well as a
management challenge. The identification of tumor origin in metastatic
patients is crucial for planning patient management and care, since many
oncology treatments include cancer-specific therapies. Moreover, these
specific therapies and related targeted therapies have been shown to lead to
increased survival of patients with advanced cancers of known origin.
Consequently, it is not a matter of whether to use microRNA profiling, but
when to use it."

About Rosetta Cancer Testing Services (formerly the miRview^® product line)
Rosetta Cancer Tests are a series of microRNA-based diagnostic testing
services offered by Rosetta Genomics. The Rosetta Cancer Origin Test^™ can
accurately identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma
Test^™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The
Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung
cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test^™
accurately classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data; it is the
treating physician's responsibility to diagnose and administer the appropriate
treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000
patients a year may benefit from the Rosetta Cancer Origin Test^™, 60,000 from
the Rosetta Mesothelioma Test^™, 65,000 from the Rosetta Kidney Cancer Test^™
and 226,000 patients from the Rosetta Lung Cancer Test^™. The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through distributors
around the world. For more information, please visit www.rosettagenomics.com.
Parties interested in ordering the test can contact Rosetta Genomics at (215)
382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000, Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's cancer testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, Rosetta's development or
commercialization of molecular diagnostics, the market acceptance of Rosetta's
cancer testing services,particularly the Rosetta Cancer Origin Test™,
Rosetta's capitalization of its microRNA platform, Rosetta's patent
positionand Rosetta's development of personalized medicine products and
servicesconstitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of Rosetta's
Annual Report on Form 20-F for the year ended December 31, 2012as filed with
the SEC. In addition, any forward-looking statements represent Rosetta's views
only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ken Berlin, President & CEO
(215) 382-9000, ext. 326
investors@rosettagenomics.com

Investor Contacts:
LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com
or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.

Website: http://www.rosettagenomics.com